23andMe to Cut Workforce by 40%, Discontinues Therapeutics Pipeline

@TheWallStreetJournal shared a link

2024-11-12 01:07:34 ·

www.wsj.com

The clinical trials 23andMe intends to wind-down include its two main therapeutic programs. The restructuring is expected to result in expenses of up to $12 million, and savings of more than $35 million per year, 23andMe said.

0 Comments ·0 Shares ·135 Views

Please log in to like, share and comment!

Upgrade to Pro

Choose the Plan That's Right for You

Upgrade